CNSX:ATT - Abattis Bioceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.29 +0.02 (+5.45 %)
(As of 06/24/2018 04:00 PM ET)
Previous CloseC$0.28
Today's RangeC$0.26 - C$0.29
52-Week RangeC$0.05 - C$0.74
Volume7.33 million shs
Average Volume1.42 million shs
Market CapitalizationC$80.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Receive ATT News and Ratings via Email

Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCNSX:ATT
CUSIPN/A
Phone+1-604-3360881

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-402.39%
Return on Assets-361.99%

Miscellaneous

EmployeesN/A
Outstanding Shares162,700,000

The Truth About Cryptocurrencies

Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the folowing people:
  • Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
  • David Whitney, Chief Financial Officer
  • Rene David, Chief Operating Officer, Director
  • Christopher P. Cherry, Corporate Controller (Age 40)
  • Hugh Oswald, IR Contact Officer
  • Christina Boddy, Corporate Secretary
  • Peter Gordon, Director
  • James Irving, Director
  • Shuang Xie, Director
  • Guy P. Dancosse QC, Independent Director

Has Abattis Bioceuticals been receiving favorable news coverage?

Media stories about ATT stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abattis Bioceuticals earned a news sentiment score of 0.03 on Accern's scale. They also gave press coverage about the company an impact score of 45.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

What is Abattis Bioceuticals' stock price today?

One share of ATT stock can currently be purchased for approximately C$0.29.

How big of a company is Abattis Bioceuticals?

Abattis Bioceuticals has a market capitalization of C$80.40 million.

How can I contact Abattis Bioceuticals?

Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.


MarketBeat Community Rating for Abattis Bioceuticals (ATT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe ATT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.